U.S. Flow Cytometry Market Size, Share & Trends Analysis Report By Product (Software, Accessories), By Technology (Cell-based, Bead-based), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
U.S. Flow Cytometry Market Growth & Trends
The U.S. flow cytometry market size is anticipated to reach USD 2.61 billion by 2030 and is growing at a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market for flow cytometry is expanding faster in the U.S. owing to increased cancer cases and other chronic illnesses. According to the American Cancer Society (ACS), there were roughly 9,270 cancer deaths among adolescents and young adults in the U.S. in 2019 who were between the ages of 15 and 39, and there were about 89,500 new cases of cancer diagnosed in 2020. These factors would drive market growth.
The COVID-19 pandemic had a positive effect on the market. For instance, in August 2020, research published in Springer discovered that flow cytometry analysis of peripheral blood mononuclear cell (PBMC) phenotype helped to predict the risk of COVID-19 clinical progression and indicated that improved antigen presentation and more effective adaptive immune responses are associated with recovery from COVID-19. The increasing frequency of infectious and chronic disorders, most notably the COVID-19 outbreak, has increased the need for technology for study and diagnosis, supporting the market's growth.
Furthermore, the U.S. has a robust healthcare infrastructure, significant healthcare spending, and widespread usage of highly advanced flow cytometry technologies. In addition, owing to research universities engaging in a wide range of research activities and having developed pharmaceutical enterprises, there is an enormous need for flow cytometry workflow for research purposes. This results from the U.S.'s substantial investment in healthcare, highly developed healthcare infrastructure, and widespread usage of cutting-edge flow cytometry technology.
U.S. Flow Cytometry Market Report Highlights
U.S. Flow Cytometry Market Growth & Trends
The U.S. flow cytometry market size is anticipated to reach USD 2.61 billion by 2030 and is growing at a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market for flow cytometry is expanding faster in the U.S. owing to increased cancer cases and other chronic illnesses. According to the American Cancer Society (ACS), there were roughly 9,270 cancer deaths among adolescents and young adults in the U.S. in 2019 who were between the ages of 15 and 39, and there were about 89,500 new cases of cancer diagnosed in 2020. These factors would drive market growth.
The COVID-19 pandemic had a positive effect on the market. For instance, in August 2020, research published in Springer discovered that flow cytometry analysis of peripheral blood mononuclear cell (PBMC) phenotype helped to predict the risk of COVID-19 clinical progression and indicated that improved antigen presentation and more effective adaptive immune responses are associated with recovery from COVID-19. The increasing frequency of infectious and chronic disorders, most notably the COVID-19 outbreak, has increased the need for technology for study and diagnosis, supporting the market's growth.
Furthermore, the U.S. has a robust healthcare infrastructure, significant healthcare spending, and widespread usage of highly advanced flow cytometry technologies. In addition, owing to research universities engaging in a wide range of research activities and having developed pharmaceutical enterprises, there is an enormous need for flow cytometry workflow for research purposes. This results from the U.S.'s substantial investment in healthcare, highly developed healthcare infrastructure, and widespread usage of cutting-edge flow cytometry technology.
U.S. Flow Cytometry Market Report Highlights
- Based on product, instrument dominated the market and accounted for 35.08% in 2023. Flow cytometry instruments are crucial in clinical diagnostics for applications such as immunophenotyping cells to monitor HIV/AIDS progression, detect minimal residual disease in leukemia, and assess immune cell function, which will fuel the segment growth
- In terms of technology, the cell-based segment dominated the market share in 2023. This technology involves analyzing cells based on their characteristics, such as size, complexity, and the presence of specific molecules. On the other hand, the bead-based segment is expected to grow at the fastest CAGR over the forecast period
- Based on application, the clinical segment held the largest market share in 2023. The industrial segment is expected to grow fastest over the forecast period
- In terms of end-use, the academic institute segment held the largest market share in 2023. Clinical testing labsare anticipated to witness the fastest growth over the forecast period
- The U.S. is the major dominating country in the market due to the surging incidence rate of diseases such as cancer and HIV amongst the population in this country, which is boosting the demand for U.S. flow cytometry market
- In January 2024, Sony Biotechnology launched the EC800, a highly versatile flow cytometry analyzer. This innovative device caters to various applications, such as particle sizing, immunophenotyping, cell viability, absolute cell counting, and apoptosis detection, among others. The EC800 offers cost-effective solutions suitablefor diverse research and diagnostic needs.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Technology
1.2.3. Application
1.2.4. End-use
1.2.5. Region
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR's internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product Outlook
2.2.2. Technology Outlook
2.2.3. Application Outlook
2.2.4. End-use Outlook
2.2.5. Regional Outlook
2.3. Competitive Insights
CHAPTER 3. U.S. FLOW CYTOMETRY MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. U.S. Flow Cytometry Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. U.S. FLOW CYTOMETRY MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Flow Cytometry Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Instruments
4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.2. Cell Analyzers
4.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.3. Cell Sorters
4.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2. Reagents & Consumables
4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.3. Software
4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.4. Accessories
4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.5. Services
4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 5. U.S. FLOW CYTOMETRY MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
5.1. Technology Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Flow Cytometry Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. Cell-based
5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.2. Bead-based
5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 6. U.S. FLOW CYTOMETRY MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Application Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Flow Cytometry Market by Application Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.4.1. Research
6.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
6.4.1.2. Pharmaceutical
6.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.2.2. Drug Discovery
6.4.1.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.2.3. In Vitro Toxicity
6.4.1.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.2.4. Stem Cell
6.4.1.2.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.3. Apoptosis
6.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.4. Cell Sorting
6.4.1.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.5. Cell Cycle Analysis
6.4.1.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.6. Immunology
6.4.1.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.7. Cell Viability
6.4.1.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.2. Industrial
6.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3. Clinical
6.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3.2. Cancer
6.4.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3.3. Organ Transplantation
6.4.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3.4. Immunodeficiency
6.4.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3.5. Hematology
6.4.3.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3.6. Autoimmune Disorders
6.4.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. U.S. FLOW CYTOMETRY MARKET: END-USE ESTIMATES & TREND ANALYSIS
7.1. End-use Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. U.S. Flow Cytometry Market by End-use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
7.4.1. Clinical Testing Labs
7.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.2. Academic Institutes
7.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3. Commercial Organizations
7.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3.2. Biotechnology Companies
7.4.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3.3. Pharmaceutical Companies
7.4.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3.4. CROs
7.4.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.4. Hospitals
7.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 8. U.S. FLOW CYTOMETRY MARKET: REGION ESTIMATES & TREND ANALYSIS
8.1. Regional Market Share, 2023 & 2030
8.2. U.S. Flow Cytometry Market by Regional Outlook
8.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
8.3.1. West
8.3.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
8.3.2. Midwest
8.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.3.3. Northeast
8.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.3.4. Southwest
8.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.3.5. Southeast
8.3.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company heat map analysis, 2023
9.4. Company Profiles
9.4.1. Sysmex Corp
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Becton, Dickinson, and Company (B.D.)
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Danaher Corp
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. Thermo Fisher Scientific, Inc.
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Agilent Technologies, Inc.
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Bio-Rad Laboratories, Inc.
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Sony Biotechnology, Inc.
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Beckman Coulter, Inc.
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Cytek Biosciences
9.4.9.1. Company overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. BioLegend, Inc.
9.4.10.1. Company overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives
9.4.11. Enzo Biochem Inc.
9.4.11.1. Company overview
9.4.11.2. Financial performance
9.4.11.3. Product benchmarking
9.4.11.4. Strategic initiatives
9.4.12. Cell Signaling Technology, Inc.
9.4.12.1. Company overview
9.4.12.2. Financial performance
9.4.12.3. Product benchmarking
9.4.12.4. Strategic initiatives
9.4.13. NeoGenomics Laboratories
9.4.13.1. Company overview
9.4.13.2. Financial performance
9.4.13.3. Product benchmarking
9.4.13.4. Strategic initiatives
9.4.14. Q2 Solutions (IQVIA)
9.4.14.1. Company overview
9.4.14.2. Financial performance
9.4.14.3. Product benchmarking
9.4.14.4. Strategic initiatives
9.4.15. Elabscience Biotechnology Inc.
9.4.15.1. Company overview
9.4.15.2. Financial performance
9.4.15.3. Product benchmarking
9.4.15.4. Strategic initiatives
9.4.16. Stratedigm, Inc.
9.4.16.1. Company overview
9.4.16.2. Financial performance
9.4.16.3. Product benchmarking
9.4.16.4. Strategic initiatives
9.4.17. BioLegend, Inc.
9.4.17.1. Company overview
9.4.17.2. Financial performance
9.4.17.3. Product benchmarking
9.4.17.4. Strategic initiatives
9.4.18. Union Biometrica, Inc.
9.4.18.1. Company overview
9.4.18.2. Financial performance
9.4.18.3. Product benchmarking
9.4.18.4. Strategic initiatives
9.4.19. BennuBio Inc.
9.4.19.1. Company overview
9.4.19.2. Financial performance
9.4.19.3. Product benchmarking
9.4.19.4. Strategic initiatives
9.4.20. ORLFO Technologies
9.4.20.1. Company overview
9.4.20.2. Financial performance
9.4.20.3. Product benchmarking
9.4.20.4. Strategic initiativesw
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Technology
1.2.3. Application
1.2.4. End-use
1.2.5. Region
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR's internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product Outlook
2.2.2. Technology Outlook
2.2.3. Application Outlook
2.2.4. End-use Outlook
2.2.5. Regional Outlook
2.3. Competitive Insights
CHAPTER 3. U.S. FLOW CYTOMETRY MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. U.S. Flow Cytometry Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. U.S. FLOW CYTOMETRY MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Flow Cytometry Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Instruments
4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.2. Cell Analyzers
4.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.3. Cell Sorters
4.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2. Reagents & Consumables
4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.3. Software
4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.4. Accessories
4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.5. Services
4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 5. U.S. FLOW CYTOMETRY MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
5.1. Technology Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Flow Cytometry Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. Cell-based
5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.2. Bead-based
5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 6. U.S. FLOW CYTOMETRY MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
6.1. Application Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Flow Cytometry Market by Application Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.4.1. Research
6.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
6.4.1.2. Pharmaceutical
6.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.2.2. Drug Discovery
6.4.1.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.2.3. In Vitro Toxicity
6.4.1.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.2.4. Stem Cell
6.4.1.2.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.3. Apoptosis
6.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.4. Cell Sorting
6.4.1.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.5. Cell Cycle Analysis
6.4.1.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.6. Immunology
6.4.1.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.1.7. Cell Viability
6.4.1.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.2. Industrial
6.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3. Clinical
6.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3.2. Cancer
6.4.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3.3. Organ Transplantation
6.4.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3.4. Immunodeficiency
6.4.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3.5. Hematology
6.4.3.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3.6. Autoimmune Disorders
6.4.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. U.S. FLOW CYTOMETRY MARKET: END-USE ESTIMATES & TREND ANALYSIS
7.1. End-use Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. U.S. Flow Cytometry Market by End-use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
7.4.1. Clinical Testing Labs
7.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.2. Academic Institutes
7.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3. Commercial Organizations
7.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3.2. Biotechnology Companies
7.4.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3.3. Pharmaceutical Companies
7.4.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3.4. CROs
7.4.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.4. Hospitals
7.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 8. U.S. FLOW CYTOMETRY MARKET: REGION ESTIMATES & TREND ANALYSIS
8.1. Regional Market Share, 2023 & 2030
8.2. U.S. Flow Cytometry Market by Regional Outlook
8.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
8.3.1. West
8.3.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
8.3.2. Midwest
8.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.3.3. Northeast
8.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.3.4. Southwest
8.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.3.5. Southeast
8.3.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company heat map analysis, 2023
9.4. Company Profiles
9.4.1. Sysmex Corp
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Becton, Dickinson, and Company (B.D.)
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Danaher Corp
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. Thermo Fisher Scientific, Inc.
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Agilent Technologies, Inc.
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Bio-Rad Laboratories, Inc.
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Sony Biotechnology, Inc.
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Beckman Coulter, Inc.
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Cytek Biosciences
9.4.9.1. Company overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. BioLegend, Inc.
9.4.10.1. Company overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives
9.4.11. Enzo Biochem Inc.
9.4.11.1. Company overview
9.4.11.2. Financial performance
9.4.11.3. Product benchmarking
9.4.11.4. Strategic initiatives
9.4.12. Cell Signaling Technology, Inc.
9.4.12.1. Company overview
9.4.12.2. Financial performance
9.4.12.3. Product benchmarking
9.4.12.4. Strategic initiatives
9.4.13. NeoGenomics Laboratories
9.4.13.1. Company overview
9.4.13.2. Financial performance
9.4.13.3. Product benchmarking
9.4.13.4. Strategic initiatives
9.4.14. Q2 Solutions (IQVIA)
9.4.14.1. Company overview
9.4.14.2. Financial performance
9.4.14.3. Product benchmarking
9.4.14.4. Strategic initiatives
9.4.15. Elabscience Biotechnology Inc.
9.4.15.1. Company overview
9.4.15.2. Financial performance
9.4.15.3. Product benchmarking
9.4.15.4. Strategic initiatives
9.4.16. Stratedigm, Inc.
9.4.16.1. Company overview
9.4.16.2. Financial performance
9.4.16.3. Product benchmarking
9.4.16.4. Strategic initiatives
9.4.17. BioLegend, Inc.
9.4.17.1. Company overview
9.4.17.2. Financial performance
9.4.17.3. Product benchmarking
9.4.17.4. Strategic initiatives
9.4.18. Union Biometrica, Inc.
9.4.18.1. Company overview
9.4.18.2. Financial performance
9.4.18.3. Product benchmarking
9.4.18.4. Strategic initiatives
9.4.19. BennuBio Inc.
9.4.19.1. Company overview
9.4.19.2. Financial performance
9.4.19.3. Product benchmarking
9.4.19.4. Strategic initiatives
9.4.20. ORLFO Technologies
9.4.20.1. Company overview
9.4.20.2. Financial performance
9.4.20.3. Product benchmarking
9.4.20.4. Strategic initiativesw
LIST OF TABLES
Table 1 List of abbreviations
Table 2 List of secondary sources
Table 3 U.S. flow cytometry market by product, 2018 - 2030 (USD Million)
Table 4 U.S. flow cytometry market by technology, 2018 - 2030 (USD Million)
Table 5 U.S. flow cytometry market by application, 2018 - 2030 (USD Million)
Table 6 U.S. flow cytometry market by end-use, 2018 - 2030 (USD Million)
Table 7 U.S. flow cytometry market by region, 2018 - 2030 (USD Million)
Table 1 List of abbreviations
Table 2 List of secondary sources
Table 3 U.S. flow cytometry market by product, 2018 - 2030 (USD Million)
Table 4 U.S. flow cytometry market by technology, 2018 - 2030 (USD Million)
Table 5 U.S. flow cytometry market by application, 2018 - 2030 (USD Million)
Table 6 U.S. flow cytometry market by end-use, 2018 - 2030 (USD Million)
Table 7 U.S. flow cytometry market by region, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. flow cytometry market: market outlook
Fig. 9 U.S. flow cytometry competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 U.S. flow cytometry market driver impact
Fig. 15 U.S. flow cytometry market restraint impact
Fig. 16 U.S. flow cytometry market strategic initiatives analysis
Fig. 17 U.S. flow cytometry market: Product movement analysis
Fig. 18 U.S. flow cytometry market: Product outlook and key takeaways
Fig. 19 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Cell analyzers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Cell sorters market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Reagents & consumables estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Software market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Accessories estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Services market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 U.S. flow cytometry market: Technology movement analysis
Fig. 27 U.S. flow cytometry market: Technology outlook and key takeaways
Fig. 28 Cell-based market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Bead-based market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 U.S. flow cytometry market: Application movement analysis
Fig. 31 U.S. flow cytometry market: Application outlook and key takeaways
Fig. 32 Research market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Drug discovery market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 In vitro toxicity market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Stem cell market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Apoptosis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Cell sorting market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Cell cycle analysis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Immunology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Cell viability market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Industrial market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Organ transplantation market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Immunodeficiency market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Hematology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Autoimmune disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 U.S. flow cytometry market: End-use movement analysis
Fig. 50 U.S. flow cytometry market: End-use outlook and key takeaways
Fig. 51 Clinical testing labs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Commercial organizations market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 CROs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 U.S. flow cytometry market: Regional movement analysis
Fig. 59 U.S. flow cytometry market: Regional outlook and key takeaways
Fig. 60 West market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. flow cytometry market: market outlook
Fig. 9 U.S. flow cytometry competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 U.S. flow cytometry market driver impact
Fig. 15 U.S. flow cytometry market restraint impact
Fig. 16 U.S. flow cytometry market strategic initiatives analysis
Fig. 17 U.S. flow cytometry market: Product movement analysis
Fig. 18 U.S. flow cytometry market: Product outlook and key takeaways
Fig. 19 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Cell analyzers market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Cell sorters market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Reagents & consumables estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Software market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Accessories estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Services market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 U.S. flow cytometry market: Technology movement analysis
Fig. 27 U.S. flow cytometry market: Technology outlook and key takeaways
Fig. 28 Cell-based market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Bead-based market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 U.S. flow cytometry market: Application movement analysis
Fig. 31 U.S. flow cytometry market: Application outlook and key takeaways
Fig. 32 Research market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Drug discovery market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 In vitro toxicity market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Stem cell market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Apoptosis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Cell sorting market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Cell cycle analysis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Immunology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Cell viability market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Industrial market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Organ transplantation market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Immunodeficiency market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Hematology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Autoimmune disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 U.S. flow cytometry market: End-use movement analysis
Fig. 50 U.S. flow cytometry market: End-use outlook and key takeaways
Fig. 51 Clinical testing labs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Commercial organizations market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 CROs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 U.S. flow cytometry market: Regional movement analysis
Fig. 59 U.S. flow cytometry market: Regional outlook and key takeaways
Fig. 60 West market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
